Analysts Set Rallybio Co. (NASDAQ:RLYB) PT at $9.75

Rallybio Co. (NASDAQ:RLYB) has been given a consensus recommendation of “Hold” by the five analysts that are presently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $9.33.

RLYB has been the topic of several research analyst reports. Citizens Jmp downgraded Rallybio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, April 8th. HC Wainwright reaffirmed a “neutral” rating on shares of Rallybio in a report on Wednesday.

Rallybio Stock Performance

RLYB opened at $0.25 on Thursday. Rallybio has a twelve month low of $0.22 and a twelve month high of $2.77. The business has a 50 day moving average price of $0.64 and a 200 day moving average price of $0.89. The firm has a market cap of $10.42 million, a P/E ratio of -0.16 and a beta of -1.35.

Rallybio (NASDAQ:RLYB) last issued its quarterly earnings data on Thursday, March 13th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.02. The firm had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.15 million. As a group, analysts anticipate that Rallybio will post -1.34 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in RLYB. Northeast Financial Consultants Inc grew its position in Rallybio by 336.5% during the fourth quarter. Northeast Financial Consultants Inc now owns 96,422 shares of the company’s stock worth $93,000 after buying an additional 74,334 shares in the last quarter. Allostery Investments LP bought a new stake in shares of Rallybio in the 4th quarter worth approximately $771,000. Almitas Capital LLC grew its holdings in shares of Rallybio by 48.3% during the 4th quarter. Almitas Capital LLC now owns 1,298,119 shares of the company’s stock worth $1,246,000 after purchasing an additional 422,685 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Rallybio by 9.3% during the fourth quarter. Renaissance Technologies LLC now owns 441,318 shares of the company’s stock valued at $424,000 after purchasing an additional 37,618 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of Rallybio by 11.4% in the third quarter. Geode Capital Management LLC now owns 244,986 shares of the company’s stock valued at $287,000 after purchasing an additional 24,980 shares in the last quarter. Institutional investors and hedge funds own 90.34% of the company’s stock.

Rallybio Company Profile

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.